Lexology February 13, 2025
The healthcare and life sciences sector is expected to lead in deal activity this year. What that will look like depends on valuations, interest rates, and compliance with a complex global regulatory landscape. Companies in the sector will need to consider all factors before proceeding with a deal, whether it be through M&A, an IPO or licensing.
Innovative therapies catch investors’ attention
Expect greater emphasis on breakthrough therapies. Investors will likely focus on companies with strong pipelines and promising clinical data, anticipating high returns from successful market entries. Adam Farlow, partner, London, says, “Market conditions are continuing to improve. While 2025 will not be a banner year, there is growing optimism that the right deals will get done. The winners...
Today's Sponsors
Today's Sponsor